AKT1 and thyroid cancer: In our study, NVP-BEZ235 administration in thyroid cancer cell lines successfully inhibited Akt phosphorylation, hence, promoted downstream FOXO3a accumulation and nuclear translocation 24, and demonstrated remarkable anti-proliferation ability via inducing cell cycle arrest.